TCBP Enters Research Planning Collaboration With Dr. Carlos Maluquer de Motes For The Development Of A Treatment For Mpox
Portfolio Pulse from Benzinga Newsdesk
TC BioPharm (NASDAQ:TCBP) has entered a research collaboration with Dr. Carlos Maluquer de Motes to develop a treatment for Monkeypox. This partnership aims to leverage expertise in viral diseases and immune response.
October 22, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TC BioPharm has announced a collaboration with Dr. Carlos Maluquer de Motes to develop a treatment for Monkeypox, potentially expanding their research capabilities and product pipeline.
The collaboration with a renowned virologist for developing a Monkeypox treatment could enhance TCBP's research capabilities and product offerings, likely having a positive impact on their stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100